Samsung Biologics Co.,Ltd. (207940.KS)

KRW 959000.0

(-2.14%)

Total Liabilities Summary of Samsung Biologics Co.,Ltd.

Samsung Biologics Co.,Ltd.'s latest annual total liabilities in 2023 was 6215.7 Billion KRW , down -18.19% from previous year.
Samsung Biologics Co.,Ltd.'s latest quarterly total liabilities in 2024 Q2 was 6014.32 Billion KRW , down -7.65% from previous quarter.
Samsung Biologics Co.,Ltd. reported annual total liabilities of 7597.57 Billion KRW in 2022, up 155.05% from previous year.
Samsung Biologics Co.,Ltd. reported annual total liabilities of 2978.9 Billion KRW in 2021, up 63.19% from previous year.
Samsung Biologics Co.,Ltd. reported quarterly total liabilities of 6512.75 Billion KRW for 2024 Q1, up 4.78% from previous quarter.
Samsung Biologics Co.,Ltd. reported quarterly total liabilities of 6390.77 Billion KRW for 2023 Q2, down -11.92% from previous quarter.

Annual Total Liabilities Chart of Samsung Biologics Co.,Ltd. (2023 - 2014)

Historical Annual Total Liabilities of Samsung Biologics Co.,Ltd. (2023 - 2014)

Year	Total Liabilities	Total Liabilities Growth
2023	6215.7 Billion KRW	-18.19%
2022	7597.57 Billion KRW	155.05%
2021	2978.9 Billion KRW	63.19%
2020	1825.41 Billion KRW	17.23%
2019	1557.17 Billion KRW	-14.67%
2018	1824.94 Billion KRW	-43.09%
2017	3206.64 Billion KRW	-7.07%
2016	3450.63 Billion KRW	8.32%
2015	3185.65 Billion KRW	339.42%
2014	724.96 Billion KRW	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q2	6014.32 Billion KRW	-7.65%
2024 Q1	6512.75 Billion KRW	4.78%
2023 Q2	6390.77 Billion KRW	-11.92%
2023 Q3	6341.64 Billion KRW	-0.77%
2023 Q4	6215.7 Billion KRW	-1.99%
2023 FY	6215.7 Billion KRW	-18.19%
2023 Q1	7255.29 Billion KRW	-4.51%
2022 FY	7597.57 Billion KRW	155.05%
2022 Q4	7597.57 Billion KRW	1.56%
2022 Q3	7481.15 Billion KRW	4.2%
2022 Q1	3676.4 Billion KRW	23.41%
2022 Q2	7179.55 Billion KRW	95.29%
2021 Q2	1829.98 Billion KRW	0.59%
2021 Q4	2978.9 Billion KRW	11.1%
2021 Q1	1819.24 Billion KRW	-0.34%
2021 FY	2978.9 Billion KRW	63.19%
2021 Q3	2681.27 Billion KRW	46.52%
2020 Q1	1553.37 Billion KRW	-0.24%
2020 Q2	1589.67 Billion KRW	2.34%
2020 Q3	1638.36 Billion KRW	3.06%
2020 FY	1825.41 Billion KRW	17.23%
2020 Q4	1825.41 Billion KRW	11.42%
2019 Q4	1557.17 Billion KRW	-4.92%
2019 FY	1557.17 Billion KRW	-14.67%
2019 Q3	1637.68 Billion KRW	-4.98%
2019 Q2	1723.51 Billion KRW	-2.71%
2019 Q1	1771.5 Billion KRW	-2.93%
2018 FY	1824.94 Billion KRW	-43.09%
2018 Q1	3363.68 Billion KRW	4.9%
2018 Q2	3581.65 Billion KRW	6.48%
2018 Q3	3576.73 Billion KRW	-0.14%
2018 Q4	1824.94 Billion KRW	-48.98%
2017 Q2	3092.26 Billion KRW	-2.61%
2017 Q1	3175.19 Billion KRW	-7.98%
2017 FY	3206.64 Billion KRW	-7.07%
2017 Q3	3117.13 Billion KRW	0.8%
2017 Q4	3206.64 Billion KRW	2.87%
2016 FY	3450.63 Billion KRW	8.32%
2016 Q4	3450.63 Billion KRW	0.0%
2015 FY	3185.65 Billion KRW	339.42%
2014 FY	724.96 Billion KRW	0.0%

Peer Total Liabilities Comparison of Samsung Biologics Co.,Ltd.

Name	Total Liabilities	Total Liabilities Difference
ORIENT BIO Inc.	11.89 Billion KRW	-52168.797%
Green Cross Holdings Corporation	1856.16 Billion KRW	-234.868%
Green Cross Holdings Corporation	1103.45 Billion KRW	-463.297%
Pharmicell Co., Ltd.	18.79 Billion KRW	-32972.217%
Green Cross Corporation	1103.45 Billion KRW	-463.297%
GeneOne Life Science, Inc.	39.51 Billion KRW	-15628.596%
Celltrion, Inc.	2791.73 Billion KRW	-122.646%
SK bioscience Co.,Ltd.	148.58 Billion KRW	-4083.297%
SK Biopharmaceuticals Co., Ltd.	402.21 Billion KRW	-1445.352%
Prestige BioPharma Limited	196.21 Billion KRW	-3067.745%